Matrix metalloproteinases, inflammation and atherosclerosis: Therapeutic perspectives

Clinical Chemistry and Laboratory Medicine

Volumn 42, Issue 2, 2004, Pages 121-131

  Beaudeux, Jean Louis ^a   Giral, Philippe ^a   Bruckert, Eric ^a   Foglietti, Marie José ^a   Chapman, M John ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Atherosclerosis; Extracellular matrix; Inflammation; Inhibition; Metalloproteinase; Therapeutics

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; BATIMASTAT; CERIVASTATIN; CGS 27023; CGS 27023A; DOXYCYCLINE; ENZYME PRECURSOR; FLUINDOSTATIN; GELATINASE A; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERSTITIAL COLLAGENASE; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PITAVASTATIN; PRAVASTATIN; PRINOMASTAT; PSEUDOPEPTIDE; REBIMASTAT; SIMVASTATIN; STROMELYSIN; TANOMASTAT; TETRACYCLINE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; DRUG DESIGN; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME REGULATION; ENZYME STRUCTURE; EXTRACELLULAR MATRIX; GENETIC POLYMORPHISM; HEART VENTRICLE REMODELING; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; ARTERIOSCLEROSIS; ENZYME INHIBITORS; HUMANS; INFLAMMATION; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 1642443944     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2004.024     Document Type: Review

References (78)

1. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999;138:419-20.
2. Georges SJ. Tissue inhibitors of metalloproteinases and metalloproteinases in atherosclerosis. Curr Opin Lipidol 1998;9:413-23.
3. Nikkari ST, Geary RL, Hatsukami T, Ferguson M, Forough, Alpers CE. Expression of collagen, interstitial collagenase, and tissue inhibitor of metalloproteinase-1 in restenosis after carotid endarterectomy. Am J Pathol 1996;148:777-83.
4. Sukhova Gk, Schonbeck U, Rabkin E, Scoen FJ, Poole R, Billinghurst RC, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999;99:2503-9.
5. Moreau M, Brocheriou I, Petit L, Ninio E, Chapman MJ, Rouis M. Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: relevance to stability of atherosclerotic plaque. Circulation 1999;99:420-6.
6. Forget MA, Desrosiers RR, Beliveau R. Physiological roles of matrix metalloproteinases: Implications for tumor growth and metastasis. Can J Physiol Pharmacol 1999;77:465-80.
7. Kerrigan JJ, Mansell JP, Sandy JR. Matrix turnover. J Orthod 2000;27:227-33.
8. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: Biological activity and clinical applications. J Clin Oncol 2000;18:1135-49.
9. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Structure, function, and biochemistry. Circ Res 2003;92:827-39.
10. Henney AM, Ye S, Zhang B, Jormsjo S, Whatling C, Erikson P, et al. Genetic diversity in the matrix metalloproteinase family: Effects on function and disease progression. Ann N Y Acad Sci 2000;902:27-38.
11. Kirchheimer JC, Remold HG. Functional characteristics of receptor-bound urokinase on human monocytes: Catalytic efficiency and susceptibility to inactivation by plasminogen activator inhibitors. Blood 1989;74:1396-402.
12. Estreicher A, Wohlwend A, Belin D, Schleuning WD, Vassalli JD. Characterization of the cellular binding site for the urokinase-type plasminogen activator. J Biol Chem 1989;264:1180-9.
13. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993;91:2546-51.
14. Hayakawa T, Yamashita K, Chuchi E, Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci 1994;107:2373-9.
15. George SJ, Lioyd CT, Angelini GD, Newby AC, Baker AH. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor metalloproteinase-3. Circulation 2000;101:296-304.
16. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002;21:2245-52.
17. Bobik A, Tkachuk V. Metalloproteinases and plasminogen activators in vessel remodelling. Curr Hypertens Rep 2003;5:466-72.
18. Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases. A review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003;59:812-23.
19. Li Z, Li L, Zielke HR, Cheng L, Xiao R, Crow MT, et al. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol 1996;148:121-8.
20. Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridation. Proc Natl Acad Sci USA 1991;88:8154-8.
21. Galis ZS, Sukhova GK, Libby P. Microscopic localization of active proteases by in situ zymography: Detection of matrix metalloproteinase activity in vascular tissue. FASEB J 1995;9:974-80.
22. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-503.
23. Saito S, Zempo N, Yamashita A, Takenaka H, Fujioka K, Esato K. Matrix metalloproteinase expressions in arteriosclerotic aneurysmal disease. Vasc Endovasc Surg 2002;36:1-7.
24. Carrell TWG, Burnand KG, Wells GMA, Clements JM, Smith A. Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms. Circulation 2002;105:477-82.
25. Moreau M, Brocheriou I, Petit L, Ninio E, Chapman MJ, Rouis M. Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: relevance to stability of atherosclerotic plaque. Circulation 1999;99:420-6.
26. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996;98:2572-9.
27. Huang Y, Mironova M, Lopes-Virella MF. Oxidized LDL stimulates matrix metalloproteinase-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 1999;19:2640-7.
28. Uzui H, Harpf A, Liu M, Doherty TM, Shukla A, Chai NN, et al. Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: Role of activated macrophages and inflammatory cytokines. Circulation 2002;106:3024-30.
29. Rouis M, Adamy C, Duverger N, Lesnik P, Horellou P, Moreau M, et al. Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation 1999;100:533-40.
30. Lemaitre V, O'Byrne TK, Borczuk AC, Okada Y, Tall AR, D'Armiento J. ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. J Clin Invest 2001;107:1227-34.
31. Silence J, Lupu F, Collen D, Lijnen HR. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol 2001;21:1440-5.
32. Galis ZS, Johnson C, Godin D, Magid R, Shipley JM, Senior RM, et al. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodelling. Circ Res 2002a;91:852-9.
33. Lemaitre V, Soloway PD, D'Armiento J. Increased medial degradation with pseudo-aneurysm formation in apolipoprotein E-knockout mice deficient in tissue inhibitor of metalloproteinases-1. Circulation 2003;107:333-8.
34. Silence J, Collen D, Lijnen HR. Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with activation of the tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) gene. Circ Res 2002;90:897-903.
35. Shi W, Brown MD, Wang X, Wong J, Kallmes DF, Matsumoto AH, et al. Genetic backgrounds but not sizes of atherosclerotic lesions determine medial destruction in the aortic root of apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003;23:1901-6.
36. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ Res 2002b;90:251-62.
37. Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM. Preliminary report: Genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995;73:209-15.
38. Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 1996;271:13055-60.
39. Terashima M, Akita H, Kanazawa K, Inoue N, Yamada S, Ito K, et al. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation 1999;99:2717-9.
40. Rauramaa R, Vaisanen SB, Luong LA, Schmidt-Trucksass A, Penttila IM, Bouchard C, et al. Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 2000;20:2657-62.
41. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-85.
42. Zhang B, Ye S, Herrmann SM, Eriksson P, De Maat M, Evans A, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary. Circulation 1999;20:2657-62.
43. Lamblin N, Bauters C, Hermant X, Lablanche JM, Helbecque N, Amouyel P. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol 2002;40:43-8.
44. Ye S, Gale CR, Martyn CN. Variation in the matrix metalloproteinase-1 gene and risk of coronary heart disease. Eur Heart J 2003;24:1668-71.
45. Steinberg J, Fink G, Picone A, Searles B, Schiller H, Lee HM, et al. Evidence of increased matrix metalloproteinase-9 concentration in patients following cardiopulmonary bypass. J Extra Corpor Technol 2001;33:218-22.
46. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, et al. Peripheral blood levels of matrix metalloproteinases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998;32:368-72.
47. Noji Y, Kajinami K, Kawashiri M, Todo Y, Horita T, Nohara A, et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med 2001;39:380-4.
48. Dorent R, Beaudeux JL, Tezenas S, Ghossoub JJ, Roussouliere AL, Leger P, et al. Circulating levels of matrix metalloproteinases in heart transplant recipients. Transplant Proc 2000;32:2750-1.
49. Beaudeux JL, Giral P, Bruckert E, Bernard M, Foglietti MJ, Chapman MJ. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia. Atherosclerosis 2003;169:139-46.
50. Jackson C, Nguyen M, Arkell J, Sambrook P. Selective matrix metalloproteinase (MMP) inhibition in rheumatoid arthritis-targetting gelatinase A activation. Inflamm Res 2001;50:183-6.
51. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): The beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 2003;22:177-203.
52. Mandal M, Mandal A, Das S, Chakraborti T, Sajal C. Clinical implications of matrix metalloproteinases. Mol Cell Biochem 2003;252:305-29.
53. D'Armiento J. Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction. Trends Cardiovasc Med 2002;12:97-101.
54. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: A new approach to prevent heart failure? Circ Res 2001;89:201-10.
55. George SJ. Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis. Expert Opin Investig Drugs 2000;9:993-1007.
56. Miralles M, Wester W, Sicard GA, Thompson R, Reilly JM. Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase. J Vasc Surg 1999;29:884-93.
57. 2 synthesis in abdominal aortic aneurysms: Implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation 1999;100:48-54.
58. Nagase H, Brew K. Engineering of tissue inhibitor of metalloproteinases mutants as potential therapeutics. Arthritis Res 2002;4Suppl 3:S51-61.
59. Dollery CM, Humphries SE, McClelland A, Latchman DS, McEwan JR. Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury. Circulation 1999;99:3199-205.
60. Hu Y, Baker AH, Zou Y, Newby AC, Xu Q. Local gene transfer of tissue inhibitor of metalloproteinase-2 influences vein graft remodeling in a mouse model. Arterioscler Thromb Vasc Biol 2001;21:1275-80.
61. Bigatel DA, Elmore JR, Carey DJ, Cizmeci-Smith G, Franklin DP, Youkey JR. The matrix metalloproteinase inhibitor BB-94 limits expansion of experimental abdominal aortic aneurysms. J Vasc Surg 1999;29:130-9.
62. Treharne GD, Boyle JR, Goodall S, Loftus IM, Bell PR, Thompson MM. Marimastat inhibits elastin degradation and matrix metalloproteinase 2 activity in a model of aneurysm disease. Br J Surg 1999;86:1053-8.
63. Loftus IM, Porter K, Peterson M, Boyle J, London NM, Bell PR, et al. MMP inhibition reduces intimal hyperplasia in a human vein graft stenosis model. Ann NY Acad Sci 1999;878:547-50.
64. Manning MW, Casis ML, Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2003;23:483-8.
65. Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC, Thompson RW. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: Preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg 1996;23:336-46.
66. Bendeck MP, Conte M, Zhang M, Nili N, Strauss BH, Farwell SM. Doxycycline modulates smooth muscle cell growth, migration, and matrix remodelling after arterial injury. Am J Pathol 2003;160:1089-95.
67. Thompson RW, Baxter BT. MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial. Ann NY Acad Sci 1999;878:159-78.
68. Axisa B, Loftus IM, Naylor R, Goodall S, Jones L, Peter RF, et al. Prospective, randomized, double-blind trial investigating effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke 2002;33:2858-64.
69. Napoli C. MMP inhibition and the development of cerebrovascular atherosclerosis: The road ahead. Stroke 2002;33:2864-5.
70. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Pleiotropic effects of statins: Lipid reduction and beyond. J Clin Endocrinol Metab 2002;87:1451-8.
71. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) Study. The CARE Investigators. Circulation 1999;99:216-23.
72. Ballantyne CM, Herd JA, Ferlic LL, Dunn JK, Farmer JA, Jones PH, et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 1999;99:736-43.
73. Corti R, Fayad ZA, Fuster V, Worthley SG, Helft G, Chesebro J, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: A longitudinal study by high-resolution, non-invasive magnetic resonance imaging. Circulation 2001;104:249-52.
74. Porter KE, Turner NA. Statins for the prevention of vein graft stenosis: A role for inhibition of matrix metalloproteinase-9. Biochem Soc Trans 2002;30:120-6.
75. Ganne F, Vasse M, Beaudeux JL, Peynet J, François A, Mishal Z, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes: A possible protective mechanism against atherothrombosis. Thromb Haemost 2000;84:680-8.
76. Suzuki H, Kabayashi H, Sato F, Yonemitsu Y, Nakashima Y, Sueishi K. Plaque-stabilizing effect of pivastatin in Watanabe heritable hyperlipidemic (WHHL) rabbits. J Atheroscler Thromb 2003;10:109-16.
77. Son JW, Koh KK, Ahn JY, Jin DK, Park GS, Kim DS, et al. Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. Int J Cardiol 2003;88:77-82.
78. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation 2001;103:926-33.